Teleflex (TFX) – StreetInsider.com Reports
-
Teleflex (TFX) PT Lowered to $240 at Truist Securities
-
Teleflex (TFX) Introduces UroLift 2 System
-
Teleflex (TFX) PT Lowered to $265 at Truist Securities
-
Teleflex (TFX) PT Lowered to $265 at RBC Capital
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 0.5% Yield
-
Teleflex (TFX) Tops Q4 EPS by 12c, provides guidance
-
Teleflex (TFX) PT Raised to $272 at RBC Capital
-
Teleflex (TFX) PT Raised to $270 at Truist Securities
-
Teleflex (TFX) PT Raised to $265 at Wells Fargo
-
Morgan Stanley Upgrades Teleflex (TFX) to Overweight
-
Teleflex (TFX) Reports Large-Scale Real-World Study Demystifies UroLift System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatme
-
Teleflex (TFX) PT Raised to $221 at Truist Securities
-
Teleflex (TFX) PT Raised to $225 at Piper Sandler
-
Teleflex (TFX) PT Raised to $235 at Mizuho Securities
-
Teleflex (TFX) PT Raised to $228 at RBC Capital
-
Teleflex (TFX) Tops Q3 EPS by 37c, updates guidance
-
Teleflex (TFX) PT Lowered to $225 at Mizuho Securities
-
Teleflex (TFX) PT Lowered to $210 at Truist Securities
-
Teleflex (TFX) PT Lowered to $210 at Piper Sandler
-
Teleflex (TFX) PT Lowered to $255 at Truist Securities
-
Teleflex (TFX) PT Lowered to $236 at Wells Fargo
-
Teleflex (TFX) PT Lowered to $315 at JMP Securities
-
Teleflex (TFX) Tops Q2 EPS by 20c
-
Teleflex (TFX) Granted FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage
-
Teleflex (TFX) PT Raised to $315 at Stephens
-
Teleflex (TFX) Acquires Palette Life Sciences
-
Teleflex (TFX) Wins National Group Purchasing Agreements with Premier
-
FDA Says Teleflex (TFX) Recalling Arrow Endurance Catheter System
-
Teleflex stock drops following Needham’s downgrade
-
Needham & Company Downgrades Teleflex (TFX) to Hold; 'UroLift Expectations May Still Be Too High'
-
Teleflex (TFX) Partners with Insighters Medical for Exclusive Distribution of the Insighters Video Laryngoscope System
-
Teleflex (TFX) Receives FDA Clearance for the Wattson Temporary Pacing Guidewire
-
Teleflex (TFX) Announces the Arrow EZ-IO Needle Is FDA Cleared For Use in an MRI Environment
-
Teleflex (TFX) Awarded Agreements with Premier
-
CL King Starts Teleflex (TFX) at Buy
-
Morgan Stanley Assumes Teleflex (TFX) at Equalweight
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 0.5% Yield
-
Teleflex (TFX) PT Raised to $305 at Stephens
-
Teleflex (TFX) Reports New Data Showing Early Intervention with the UroLift System Facilitates Long-Term Outcomes for BPH Patients
-
Teleflex (TFX) Launches New Arrow VPS Rhythm DLX Device and NaviCurve Stylet in the US
-
Wolfe Research Downgrades Teleflex (TFX) to Peerperform
-
Teleflex (TFX) PT Raised to $264 at Truist Securities
-
Teleflex (TFX) PT Lowered to $250 at Truist Securities
-
CFRA Upgrades Teleflex (TFX) to Buy
-
Teleflex (TFX) PT Lowered to $290 at Stephens
-
Teleflex (TFX) PT Raised to $259 at Raymond James
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 0.6% Yield
-
Teleflex (TFX) Tops Q4 EPS by 8c
-
Teleflex (TFX) Granted FDA 510(K) Clearance for Triumph Catheter and GuideLiner Coast Catheter
-
Teleflex (TFX) PT Lowered to $260 at Truist Securities
Back to TFX Stock Lookup